黏液性卵巢癌的最新研究进展。
Recent Insights into Mucinous Ovarian Carcinoma.
机构信息
IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Laboratory of Molecular Pharmacology, Via Giuseppe La Masa 19, 20156 Milan, Italy.
出版信息
Int J Mol Sci. 2018 May 24;19(6):1569. doi: 10.3390/ijms19061569.
Abstract
Ovarian mucinous tumors represent a group of rare neoplasms with a still undefined cell of origin but with an apparent progression from benign to borderline to carcinoma. Even though these tumors are different from the other histological subtypes of epithelial ovarian neoplasms, they are still treated with a similar chemotherapeutic approach. Here, we review its pathogenesis, molecular alterations, (differential) diagnosis, clinical presentation and current treatment, and how recent molecular and biological information on this tumor might lead to better and more specific clinical management of patients with mucinous ovarian carcinoma.
摘要
卵巢黏液性肿瘤是一组罕见的肿瘤，其细胞起源仍不明确，但明显具有从良性到交界性再到癌的进展过程。尽管这些肿瘤与其他组织学类型的上皮性卵巢肿瘤不同，但它们仍采用类似的化疗方法进行治疗。在这里，我们回顾了其发病机制、分子改变、（鉴别）诊断、临床表现和当前治疗方法，以及最近关于该肿瘤的分子和生物学信息如何可能导致更好和更具针对性的黏液性卵巢癌患者的临床管理。
相似文献
1
Recent Insights into Mucinous Ovarian Carcinoma.黏液性卵巢癌的最新研究进展。
Int J Mol Sci. 2018 May 24;19(6):1569. doi: 10.3390/ijms19061569.
2
Mucinous epithelial ovarian carcinoma.黏液性上皮性卵巢癌。
Ann Oncol. 2016 Apr;27 Suppl 1:i53-i57. doi: 10.1093/annonc/mdw087.
3
Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?良性、交界性和浸润性黏液性卵巢肿瘤的危险因素：肿瘤连续体的流行病学证据？
Gynecol Oncol. 2007 Nov;107(2):223-30. doi: 10.1016/j.ygyno.2007.06.006. Epub 2007 Jul 27.
4
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.卵巢癌的形态学亚型：新进展和发病机制综述。
Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7.
5
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.晚期黏液性上皮性卵巢癌：希腊肿瘤协作组的经验
Gynecol Oncol. 2005 May;97(2):436-41. doi: 10.1016/j.ygyno.2004.12.056.
6
Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.化疗在黏液性上皮性卵巢癌中的活性：一项回顾性研究。
Anticancer Res. 2005 Sep-Oct;25(5):3501-5.
7
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.黏液性上皮性卵巢癌：一种需要特定治疗的独立实体。
J Clin Oncol. 2004 Mar 15;22(6):1040-4. doi: 10.1200/JCO.2004.08.078.
8
Unmasking the complexities of mucinous ovarian carcinoma.揭开黏液性卵巢癌的复杂性。
Gynecol Oncol. 2010 Jun;117(3):491-6. doi: 10.1016/j.ygyno.2010.02.010. Epub 2010 Mar 23.
9
Clinical characteristics and prognosis of mucinous tumors of the ovary.卵巢黏液性肿瘤的临床特征与预后
Gynecol Oncol. 2006 Oct;103(1):171-5. doi: 10.1016/j.ygyno.2006.02.015. Epub 2006 Mar 20.
10
Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs.黏液性卵巢癌：当前的治疗靶点、临床前进展及实验性药物
Expert Opin Investig Drugs. 2019 Dec;28(12):1025-1029. doi: 10.1080/13543784.2019.1693999. Epub 2019 Nov 19.
引用本文的文献
1
Recent Therapies and Biomarkers in Mucinous Ovarian Carcinoma.黏液性卵巢癌的最新治疗方法和生物标志物
Cells. 2025 Aug 9;14(16):1232. doi: 10.3390/cells14161232.
2
Mucinous Ovarian Carcinoma: Integrating Molecular Stratification into Surgical and Therapeutic Management.黏液性卵巢癌：将分子分层纳入手术和治疗管理
Biomedicines. 2025 May 14;13(5):1198. doi: 10.3390/biomedicines13051198.
3
Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions.卵巢癌的早期诊断：进展、挑战及未来方向综述
Diagnostics (Basel). 2025 Feb 7;15(4):406. doi: 10.3390/diagnostics15040406.
4
Genetic landscape of homologous recombination repair and practical outcomes of PARPi therapy in ovarian cancer management.卵巢癌管理中同源重组修复的基因图谱及PARPi治疗的实际疗效
Ther Adv Med Oncol. 2024 Sep 5;16:17588359241271845. doi: 10.1177/17588359241271845. eCollection 2024.
5
A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.一种用于网络生物信息学的新方法鉴定出了黏液性卵巢癌的新药物靶点。
NAR Genom Bioinform. 2024 Aug 24;6(3):lqae096. doi: 10.1093/nargab/lqae096. eCollection 2024 Sep.
6
Multimodal diagnostic strategies and precision medicine in mucinous ovarian carcinoma: a comprehensive approach.黏液性卵巢癌的多模态诊断策略与精准医学：一种综合方法
Front Oncol. 2024 Jul 8;14:1391910. doi: 10.3389/fonc.2024.1391910. eCollection 2024.
7
Anaplastic Carcinoma Arising From a Mural Nodule in Benign Mucinous Cystadenoma.起源于良性黏液性囊腺瘤壁结节的间变性癌。
Cureus. 2024 Feb 5;16(2):e53603. doi: 10.7759/cureus.53603. eCollection 2024 Feb.
8
Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors.miRNA 比值的协同作用作为黏液性交界性和恶性卵巢肿瘤有前途的诊断生物标志物。
Int J Mol Sci. 2023 Nov 6;24(21):16016. doi: 10.3390/ijms242116016.
9
Development and validation of a nomogram to predict cancer-specific survival of mucinous epithelial ovarian cancer after cytoreductive surgery.建立并验证一个列线图模型预测黏液性卵巢上皮癌患者行细胞减灭术后的癌症特异性生存。
J Ovarian Res. 2023 Jun 27;16(1):120. doi: 10.1186/s13048-023-01213-2.
10
Histological and Genetic Diversity in Ovarian Mucinous Carcinomas: A Pilot Study.卵巢黏液性癌的组织学和遗传学多样性：一项初步研究。
Curr Oncol. 2023 Apr 4;30(4):4052-4059. doi: 10.3390/curroncol30040307.
本文引用的文献
1
Early stage mucinous ovarian cancer: A review.早期黏液性卵巢癌：综述。
Gynecol Oncol. 2018 Jun;149(3):598-604. doi: 10.1016/j.ygyno.2018.01.035. Epub 2018 Feb 9.
2
Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma.原发性卵巢黏液性癌的综合临床病理及更新的免疫组织化学特征
Int J Surg Pathol. 2018 Jun;26(4):306-317. doi: 10.1177/1066896917752861. Epub 2018 Jan 16.
3
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
4
Mutational heterogeneity in non-serous ovarian cancers.非浆液性卵巢癌中的突变异质性。
Sci Rep. 2017 Aug 29;7(1):9728. doi: 10.1038/s41598-017-10432-9.
5
IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression.IMP3在原发性卵巢黏液性癌中上调并促进肿瘤进展。
Am J Transl Res. 2017 Jul 15;9(7):3387-3398. eCollection 2017.
6
Molecular Profiling Reveals a Clonal Relationship Between Ovarian Mucinous Tumors and Corresponding Mural Carcinomatous Nodules.分子分析揭示卵巢黏液性肿瘤与其相应的壁层癌性结节之间存在克隆关系。
Am J Surg Pathol. 2017 Sep;41(9):1261-1266. doi: 10.1097/PAS.0000000000000875.
7
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.鉴定上皮性卵巢癌不同组织学类型的12个新的易感基因座。
Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27.
8
The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.黏液性卵巢癌中 Her2 扩增和 Kras 突变的状态。
Hum Genomics. 2016 Dec 28;10(1):40. doi: 10.1186/s40246-016-0096-9.
9
Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.多点Kras癌基因突变可能提示整个黏液性卵巢肿瘤谱系中的黏液性癌。
Oncotarget. 2016 Dec 13;7(50):82097-82103. doi: 10.18632/oncotarget.13449.
10
The disparate origins of ovarian cancers: pathogenesis and prevention strategies.卵巢癌的不同起源：发病机制和预防策略。
Nat Rev Cancer. 2017 Jan;17(1):65-74. doi: 10.1038/nrc.2016.113. Epub 2016 Nov 25.
Zotero 插件